|display ongoing studies|
||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 mild to moderate meta-analysis
|RCT||tocilizumab||standard of care||COVID-19 mild to moderate||some concern||64/67||inconclusive|
|RCT||tocilizumab||placebo||COVID-19 mild to moderate||some concern||259/129||conclusif|
|Capra, 2020||OBS||tocilizumab||control||COVID-19 mild to moderate||critical||62/23||suggested|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).